{"organizations": [], "uuid": "8d62a43c6af011775b9c16776f185b522f48c60b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/shire-results/shire-posts-16-pct-rise-in-full-year-earnings-sees-slower-growth-in-2018-idUSFWN1Q4112", "country": "US", "domain_rank": 408, "title": "Shire ‍posts 16 pct rise in full-year earnings, sees slower growth in 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.029, "site_type": "news", "published": "2018-02-14T20:16:00.000+02:00", "replies_count": 0, "uuid": "8d62a43c6af011775b9c16776f185b522f48c60b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/shire-results/shire-posts-16-pct-rise-in-full-year-earnings-sees-slower-growth-in-2018-idUSFWN1Q4112", "ord_in_thread": 0, "title": "Shire ‍posts 16 pct rise in full-year earnings, sees slower growth in 2018", "locations": [], "entities": {"persons": [{"name": "paul sandle", "sentiment": "none"}, {"name": "james davey", "sentiment": "none"}], "locations": [{"name": "shire", "sentiment": "none"}, {"name": "london", "sentiment": "none"}], "organizations": [{"name": "shire", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "non-gaap", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, Feb 14 (Reuters) - Shire, the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after earnings per share rose 16 percent in 2017.\nThe London-listed company on Wednesday reported full-year revenue of $15.16 billion, up 33 percent, and non-GAAP diluted earnings per ADS of $15.15, which came in towards the top of its guidance.\nReporting by Paul Sandle; editing by James Davey\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T20:16:00.000+02:00", "crawled": "2018-02-15T20:50:16.002+02:00", "highlightTitle": ""}